Investment Rating - The industry investment rating is "Outperform the Market" (expected to perform better than the CSI 300 index by more than 5% in the next 6 months) [24] Core Insights - From January to July 2025, the overall medical insurance fund income maintained positive growth, with total income reaching 1,684.66 billion yuan, a year-on-year increase of 6.93%, while expenditures decreased to 1,369.69 billion yuan, a decline of 0.95% [2][6] - The cumulative surplus of the medical insurance fund for the same period was 314.97 billion yuan, representing a year-on-year increase of 63.53%, with a surplus rate of 18.70%, up 6.48 percentage points from the same period in 2024 [2][11] Summary by Sections Medical Insurance Fund Income and Expenditure - The medical insurance fund income from January to July 2025 showed consistent growth, with monthly income figures of 314.31, 232.13, 268.15, 215.61, 199.33, 249.09, and 206.05 billion yuan, reflecting year-on-year growth rates of 10.37%, 5.72%, 0.35%, 10.02%, 3.23%, 9.34%, and 10.15% respectively [6] - In contrast, the expenditures varied, with total expenditures for the same period amounting to 1,369.69 billion yuan, showing a year-on-year decline of 0.95% [6][19] Employee and Resident Medical Insurance - Employee medical insurance income for January to July 2025 was 1,050.24 billion yuan, a year-on-year increase of 5.93%, while expenditures were 776.17 billion yuan, up 2.97% [3][19] - For urban and rural resident medical insurance, income reached 634.43 billion yuan, a year-on-year increase of 8.62%, while expenditures decreased to 593.53 billion yuan, down 5.66% [3][19] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group [4][22] - It also highlights companies with significant single-product potential and those with leading positions in advanced technology platforms [4][22] - In the CXO sector, companies like WuXi AppTec and Kelun-Biotech are recommended, along with quality medical device firms that have been undervalued due to previous price pressures [4][22]

Core Viewpoint - The article emphasizes that Kailaiying is positioned for growth through its small molecule CDMO business and emerging sectors, leveraging its technological advantages and expanding service capabilities to become a leading comprehensive CDMO service provider [3][4]. Small Molecule CDMO Business - The small molecule CDMO business is the foundation of Kailaiying's development and its largest revenue segment, benefiting from continuous reaction technology and biocatalysis, which provide a competitive edge in cost and efficiency [3][5]. - The company aims to enhance its global presence and pipeline penetration among multinational pharmaceutical companies by expanding overseas production capacity, particularly leveraging experiences from the UK Sandwich Site [3][5]. Emerging Business Segments - Kailaiying has diversified into several emerging business areas, including chemical macromolecule CDMO, formulation CDMO, biological macromolecule CDMO, clinical CRO, technology output, and synthetic biology, supported by its established R&D and quality management systems [3][5]. - The chemical macromolecule CDMO segment is expected to grow rapidly due to increasing demand for peptide and oligonucleotide drugs, with the company poised to capture market share amid supply shortages [5]. - The formulation CDMO business is anticipated to see significant growth with the introduction of new production capacities for pre-filled syringes and solid formulations by 2025 [5]. - The biological macromolecule CDMO segment, focusing on conjugated drugs, is expected to enhance both efficiency and profitability through an integrated service model [5]. - The clinical CRO business is projected to recover steadily as the innovative drug sector sees increased investment and as the company strengthens its capabilities in mid-to-late stage projects and overseas registrations [5]. Financial Projections - The company forecasts net profits of 39 million, 83 million, and 141 million yuan for 2025, 2026, and 2027, representing year-on-year growth rates of 186%, 111%, and 69% respectively, with corresponding EPS of 3.24, 3.89, and 4.71 yuan [4]. - The current stock price corresponds to PE ratios of 36, 30, and 25 for the years 2025 to 2027, indicating a favorable valuation outlook based on the company's growth potential and competitive advantages [4].

Group 1 - The company held its fifth board meeting on September 15, 2025, where all nine directors attended and approved the proposal to use temporarily idle raised funds for cash management [2][3] - The board approved the use of up to 600 million RMB of temporarily idle A-share raised funds to purchase low-risk, high-liquidity principal-protected financial products, with a usage period of 12 months from the date of approval [7][15] - The company has previously used idle raised funds for cash management, with a total of 1,655.61 million RMB utilized as of July 31, 2025, and has received 66.34 million RMB in returns from these investments [8][10] Group 2 - The company aims to improve the efficiency of idle raised funds and increase financial returns through investments in short-term, low-risk financial products [11][14] - The investment will be managed by the company's management team, with the finance department responsible for specific operations [11][15] - The company will ensure that the investment does not affect the normal construction of fundraising projects and daily operational needs [14]

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - Heng Rui Medicine (01276) saw the largest increase in ownership percentage, rising by 1.49% to a total of 13.84% [2]. - Kanglong Chemical (03759) experienced a 1.35% increase, bringing its ownership to 60.51% [2]. - Zhaoyan New Drug (06127) increased by 1.27%, reaching a holding of 43.70% [2]. - Other companies with significant increases include Junshi Biosciences (01877) at +1.24% (59.08%) and China Pacific Insurance (02601) at +1.20% (44.16%) [2]. Group 2: Decreased Holdings - Shandong Molong (00568) had the largest decrease, with a drop of 1.99% to 57.67% [2]. - Yisou Technology (02550) decreased by 0.99%, now holding 37.95% [2]. - Nanjing Panda Electronics (00553) saw a reduction of 0.98%, bringing its ownership to 42.65% [2]. - Other notable decreases include Kailai Ying (06821) at -0.95% (43.35%) and Meizhong Jiahe (02453) at -0.95% (32.06%) [2]. Group 3: Five-Day Changes - In the last five trading days, China Merchants Energy (01138) had the highest increase in ownership, up by 6.19% to 65.63% [3]. - Shandong Molong (00568) also saw a significant increase of 3.74% [3]. - Other companies with notable increases include Zhongchu Innovation (03931) at +3.62% (10.35%) and Youbao Online (02429) at +3.33% (17.38%) [3]. Group 4: Twenty-Day Changes - Over the past twenty days, Anjiren Food (02648) experienced the largest increase, up by 12.29% to 20.54% [4]. - China Merchants Energy (01138) also saw a significant increase of 9.07% [4]. - Other companies with notable increases include Yimai Sunshine (02522) at +7.70% (43.02%) and Lens Technology (06613) at +7.56% (13.64%) [4].

| 股份代號: 06821 --------- | | | --- | --- | | 上市法國名稱: 飢梨英醫與鳳凰(天津)股份有限公司 - H股 | | | 日期(日/月/年): 16/08/2025 - 16/09/2025 | | | 如欲誤看技醫權益過知之内容,請於「有關學件的日期」欄接下有關連結 · | | | *赶解:(L)-好禽(S)-汉章,(P)-可供值出的股份 | | | 製格序數 大泉車/鹽聯/最重行政人員名 作出获國的 夏入 / 寶出國志及的 蜘裂的平均價. | 持旁推动的段份數目 佔已發行的 有服裝炸的日期相關速量級份 豐權提權益 | | 新发图 | (商品開放-5) 日 有货量情段(日/月/生) 推荐 | | | 分目分析 | | | | 格隆汇9月16日丨根据联交所最新权益披露资料显示，2025年9月11日，凯莱英(06821.HK)获Schroders PLC在场内以每股均价96.7494港元增持19.76万股，涉资约1912万港元。 增持后，Schroders PLC最新持股数目为569.29万股，持股比例由19.94%上升至20.66%。 ...

Group 1 - The proposed sanctions by the Trump administration on innovative drugs have caused significant turmoil in the capital market, with the Hong Kong Hang Seng Biotechnology Index dropping by 7% at the opening, affecting leading companies like BeiGene and CSPC Pharmaceutical [1] - The National Medical Products Administration (NMPA) announced a reduction in the review and approval time for clinical trial applications to 30 working days, nearly halving the previous timeline, which has provided reassurance to the anxious market [1][8] - The U.S. aims to cut off the core profit path for Chinese innovative drugs through enhanced CFIUS reviews and increased FDA regulatory costs, while China is responding with accelerated approval processes and synchronized global research submissions [1][4] Group 2 - The Trump administration's draft executive order includes two main provisions targeting the key aspect of BD licensing for Chinese innovative drugs [2] - The first provision expands CFIUS reviews, requiring U.S. pharmaceutical companies to undergo mandatory safety reviews for acquiring rights to Chinese drugs in development, which could lead to longer transaction cycles and increased costs [3] - The second provision mandates more detailed FDA reviews of Chinese clinical data and higher regulatory fees for companies submitting trial data from China, raising the entry barriers for Chinese innovative drugs into the U.S. market [4] Group 3 - Data shows that the success rate for Chinese innovative drugs progressing from Phase I clinical trials to FDA approval is only 1.7%, highlighting the stringent nature of FDA approvals [4][6] - Currently, only two PD-1 inhibitors developed in China have received FDA approval, indicating the challenges faced by Chinese companies in the U.S. market [6] - The proposed U.S. measures may inadvertently strengthen the position of multinational corporations (MNCs) that are increasingly interested in Chinese innovative drugs due to their cost-effectiveness and high return on investment [7] Group 4 - The NMPA's recent policy to expedite clinical trial reviews is expected to significantly shorten the R&D cycle, enhancing China's attractiveness in the global R&D network and improving the bargaining power of local companies in international transactions [9][11] - The policy aims to create a more reliable domestic market as a "base" for innovative drug companies, especially when facing potential obstacles in international markets [9] - By 2025, the number of approved innovative drugs in China is projected to reach 43, with domestic drugs accounting for 93%, indicating a robust growth trajectory in the innovative drug sector [9][10] Group 5 - The Chinese government continues to support the development of innovative drugs through various policies, including the establishment of a comprehensive support system for R&D and payment mechanisms [10] - The introduction of a commercial health insurance directory for innovative drugs aims to provide new payment channels for high-value drugs, addressing the challenges of reimbursement under basic medical insurance [10] - The overall policy framework is designed to create a closed-loop system for the high-quality development of innovative drugs, enhancing clinical accessibility and stabilizing enterprise expectations [10][11]

Core Viewpoint - The company announced the approval of a proposal to utilize part of its temporarily idle raised funds for cash management, allowing for investment in low-risk financial products up to RMB 800 million [1] Group 1 - The fourth meeting of the fourth board of directors is scheduled for September 30, 2024 [1] - The company and its subsidiaries will ensure the normal implementation of fundraising projects and the safety of funds before using the idle funds [1] - The investment period for the financial products is set to be within 12 months after the board's approval [1] Group 2 - The funds can be rolled over within the approved limit of RMB 800 million [1] - The financial products to be purchased are characterized by high safety, good liquidity, and low risk [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，二零二五年九月十五日 於本公告日期，本公司董事會由董事長兼執行董事 Hao Hong 博士，執行董事楊蕊女士 、張達先生及洪亮先生，非執行董事 Ye Song 博士及張婷女士，以及獨立非執行董事孫 雪嬌博士、侯欣一博士及謝維愷先生組成。 二、募集资金使用情况及暂时闲置原因 （一）募集资金使用情况 第一创业证券承销保荐有限责任公司 截至 2025 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，二零二五年九月十五日 凯莱英医药集团（天津）股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司(以下简称"公司")于 2025 年 9 月 15 日召开第五届董事会第三次会议，审议通过了《关于使用暂时闲置募集 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 一、董事会会议召开情况 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）第五届董事会 第三次会议通知于 2025 年 9 月 9 日以电子邮件和书面形式发送给各位董事及高 级管理人员，会议于 2025 年 9 月 15 日以通讯方式召开。公司应到董事 9 名，实 到董事 9 名，公司部分高级管理人员列席了本次会议。会议由公司董事长 HAO HONG ...